{"id":"NCT02925494","sponsor":"AbbVie","briefTitle":"An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","officialTitle":"Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-14","primaryCompletion":"2018-05-07","completion":"2019-03-22","firstPosted":"2016-10-06","resultsPosted":"2020-06-30","lastUpdate":"2021-07-13"},"enrollment":433,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Uterine Fibroids","Heavy Menstrual Bleeding"],"interventions":[{"type":"DRUG","name":"Estradiol/Norethindrone Acetate","otherNames":[]},{"type":"DRUG","name":"Elagolix","otherNames":["ABT-620","elagolix sodium"]}],"arms":[{"label":"Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)","type":"EXPERIMENTAL"},{"label":"Elagolix","type":"EXPERIMENTAL"}],"summary":"This is an extension study for women who have already received six months of treatment in the phase III clinical trial M12-815 (NCT02654054) or M12-817 (NCT02691494), and will evaluate the long-term efficacy and safety of elagolix administered alone and in combination with estradiol/norethindrone acetate for an additional six months in the treatment of heavy menstrual bleeding associated with uterine fibroids.","primaryOutcome":{"measure":"Percentage of Participants Meeting the Criteria for Responder","timeFrame":"From Month 0 (Baseline in Pivotal Study) to Final Month of Treatment Period (up through Month 6 in Extension Study)","effectByArm":[{"arm":"Placebo->Elagolix","deltaMin":85.7,"sd":null},{"arm":"Placebo->Elagolix + E2/NETA","deltaMin":66.7,"sd":null},{"arm":"Elagolix->Elagolix","deltaMin":89.4,"sd":null},{"arm":"Elagolix + E2/NETA->Elagolix + E2/NETA","deltaMin":87.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":124,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["32459423","34878624"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":59},"commonTop":["HOT FLUSH","NIGHT SWEATS","HEADACHE","NAUSEA","NASOPHARYNGITIS"]}}